Registered outcomes11

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 11 of 11

List	Outcome	Time frame
Primary	Phase II: pCR evaluated by researchers	3 months after the last subject underwent RC+PLD surgery.
Primary	Phase III: EFS assessed by BICR	5 years after the first medication of the last subject.
Primary	Recommended Phase 3 Dose (RP3D)	3 months after MIBC surgery.
Secondary	ORR	From first dose to disease progression or death, whichever comes first, up to 3 years.
Secondary	DCR	From first dose to disease progression or death, whichever comes first, up to 3 years.
Secondary	pCR	Three months after MIBC surgery.
Secondary	EFS	From first dose to disease progression or death, whichever comes first, up to 3 years.
Secondary	DFS	From first dose to disease progression or death, whichever comes first, up to 3 years.
Secondary	OS	From first dose to disease progression or death, whichever comes first, up to 3 years.
Secondary	Pathological downstaging (pDS)	3 months after MIBC surgery.
Secondary	AE	From Day1 to 90 days after last dose.

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT06879145/registered